63352-56-7

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl-2,3-piperazinedione is used as a key intermediate in the synthesis of Piperacillin sodium, a widely used antibiotic. It contributes to the production of this antibiotic by facilitating the formation of the final product through a new process. This intermediate is essential for the development of effective treatments for bacterial infections, particularly those caused by gram-negative and gram-positive bacteria.

InChI:InChI=1/C11H12N2O2/c14-10-11(15)13(7-6-12-10)8-9-4-2-1-3-5-9/h1-5H,6-8H2,(H,12,14)

Upstream product

• 77917-07-8 N,N'-dibenzyl-2,3-diketopiperazine 
• 4152-09-4 N-benzylethylenediamine 
• 553-90-2 Dimethyl oxalate 
• 2759-28-6 1-phenylmethylpiperazine 

Downstream Products

• 1375301-34-0 C₁₆H₂₀N₂O₂ 
• 1375301-09-9 C₁₅H₂₀N₂O₂ 
• 1375301-10-2 C₁₄H₁₈N₂O₂ 
• 1375301-11-3 1-benzyl-4-isobutylpiperazine-2,3-dione 
• 321860-08-6 1-benzyl-4-isopropyl-piperazine-2,3-dione 
• 1375312-45-0 C₁₄H₁₆N₂O₄ 
• 1375313-00-0 C₁₆H₂₀N₂O₄ 
• 1375312-53-0 C₁₅H₁₈N₂O₄ 
• 1375312-83-6 C₁₅H₁₈N₂O₄ 
• 321860-07-5 1-benzyl-4-cyclopropyl-piperazine-2,3-dione 
• 77917-07-8 N,N'-dibenzyl-2,3-diketopiperazine 
• 1375301-15-7 C₁₅H₁₈N₂O₂ 

Relevant academic research and scientific papers

Piperazines as model substrate for oxidations

Piperazine derivatives when being oxidized by mercury-EDTA behave unusually. Due to the reactive cyclic enediamine intermediates as aza-analogous reductones and to the carbonyl compounds resulting from dehydrogenation in the side chain, there exists a high tendency of polymerization. 1-Benzylpiperazines 5a-d generate the piperazine-2,3-diones 8a-d in medium yields. From 1-benzhydrylpiperazine 11 results a mixture of piperazine-2,3-dione 12 and piperazine-3-on 13. The 1,4-bis-substituted piperazines react more differently because of the symmetry and the preferred direction of the dehydrogenation into the cycle. Thus, from 15 and 19 the diones 16 and 20, respectively, were available in very good yields. A mechanism for the reactions is proposed.

ASPARTYL PROTEASE INHIBITORS

The present invention provides compounds having formula (I): wherein R’, R0, R1, X1, R2, R3, R3’, X2, X3, and R4 are as defined herein, and pharmaceuticals compositions thereof. The present invention also provides methods of inhibiting proteases, more specially aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer’s Disease). The present invention also provides methods for preparing compounds of the invention.